Fig. 2

Effects of pharmacokinetic parameters. A Dose-normalized MPA-AUC of patients divided by eGFR level (< 81 mL/min vs ≥ 81 mL/min). B Dose-normalized MPA-AUC of patients divided by serum albumin level (< 3.5 g/dL vs ≥ 3.5 g/dL). C Dose-normalized MPA-AUC of patients with presence or absence of PPI. D Dose-normalized MPA-AUC of patients with presence or absence of metal (iron/magnesium oxide). E dose-normalized Cmax of patients divided by eGFR level (< 81 mL/min vs ≥ 81 mL/min). F Dose-normalized Cmax of patients divided by serum albumin level (< 3.5 g/dL vs ≥ 3.5 g/dL). G Dose-normalized Cmax of patients with presence or absence of PPI. H) Dose-normalized Cmax of patients with presence or absence of metal (iron/magnesium oxide). **: p < 0.01, *: p < 0.05, NS: not significant